DBV Technologies reported -30442000 in Gross Profit on Sales for its fiscal quarter ending in September of 2024.


Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.83M 19.91M Jun/2025
Alnylam Pharmaceuticals USD 630.74M 107.59M Jun/2025
Amarin USD 25.13M 1.78M Mar/2025
BioMarin Pharmaceutical USD 670.47M 76.89M Jun/2025
DBV Technologies -30442000 30.56M Sep/2024
Halozyme Therapeutics USD 279.36M 62.9M Jun/2025
Incyte USD 1.14B 151.67M Jun/2025
Insmed USD 78.08M 6.53M Jun/2025
Ionis Pharmaceuticals USD 448M 317.85M Jun/2025
Neurocrine Biosciences USD 676.2M 112.8M Jun/2025
PTC Therapeutics USD 163.39M 999.84M Jun/2025
Sarepta Therapeutics USD 457.87M 149.43M Jun/2025
Ultragenyx Pharmaceutical USD 143.49M 32.86M Jun/2025
United Therapeutics USD 711M 9.1M Jun/2025